Molecular Test Detects Bile Duct Cancer at Twice the Rate of Standard Methods
The BiliSeq molecular test detected bile duct cancer in 82% of cases—compared to 44% with standard pathology—according to a six-year, multi-institutional study.
Read MorePosted by CLP Edit Staff | Mar 31, 2026 | Cancer, Molecular Diagnostics |
The BiliSeq molecular test detected bile duct cancer in 82% of cases—compared to 44% with standard pathology—according to a six-year, multi-institutional study.
Read MorePosted by CLP Edit Staff | Mar 26, 2026 | Lab Management |
A national eMERGE study found that genetic risk results can be returned at scale, with over 70% of high-risk patients receiving counseling, though disparities in access persist, according to the American Journal of Human Genetics.
Read MorePosted by CLP Edit Staff | Mar 26, 2026 | Colorectal |
Inherited variants in the DPYD gene can increase the risk of life-threatening toxicity from fluoropyrimidine-based chemotherapies, yet screening remains inconsistent across care settings.
Read MorePosted by CLP Edit Staff | Mar 25, 2026 | Compliance |
The owner of an Oregon clinical laboratory allegedly submitted tens of millions in fraudulent claims to Medicare Advantage plans for laboratory testing services that were never ordered or performed.
Read MorePosted by CLP Edit Staff | Mar 24, 2026 | Compliance |
An Alabama-based physician received a 16-month prison sentence for signing off on medically unnecessary genetic tests and durable medical equipment orders, resulting in millions in false Medicare claims.
Read More